Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Silver nanoparticles trigger proteotoxicity in multiple myeloma cells via a mechanism distinct from bortezomib and remain efective in BTZ-resistant myeloma

Khushbu Patel, Lawrence Druhan, Timothy Pardee, Barry Paul, Steven Park, Ravi Singh

Blood (2025) 146 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2025-4322

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

Manisha Bhutani, Myra Robinson, Margarita Dzhanumova, Samantha Bradley, Adrienne Dobbins, Robin Cox, David Foureau, Shebli Atrash, Barry Paul, Cindy Varga, Christopher Ferreri, Reed Friend, Mauricio Pineda-Roman, Brittany Neelands, Joseph Mikhael, Nadine Barrett, Peter Voorhees

Blood (2025) 146 (Supplement 1): 8244.

https://doi.org/10.1182/blood-2025-8244

Published: 2025

Journal Articles

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Abena Prempeh, Myra Robinson, Zalak Shah, Ami Ndiaye, Nicole Serapin, Barry Paul, Cindy Varga, Reed Friend, Christopher Ferreri, Shebli Atrash, John Mckay, Peter Voorhees, Manisha Bhutani

Blood (2025) 146 (Supplement 1): 6347.

https://doi.org/10.1182/blood-2025-6347

Published: 2025

Journal Articles

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Blood (2025) 146 (Supplement 1): 4014.

https://doi.org/10.1182/blood-2025-4014

Published: 2025

Journal Articles

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

David Foureau, Dragos Plesca, Fei Guo, Barry Paul, Christopher Ferreri, Shebli Atrash, Cindy Varga, Reed Friend, Ami Ndiaye, Lawrence Druhan, Allison Karabinos, Jessica McElwee, Grace Elsey, Allison Morse, Meagan Reinfried, Alexandra Wolff, Peter Voorhees, Manisha Bhutani

Blood (2025) 146 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2025-4005

Published: 2025

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Abdullah Mohammad Khan, Mehak M Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyoung Tiger, Hira Shaikh, Christopher Strouse, Kimberly M Green, James A Davis, Hamza Hashmi, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend

Blood (2024) 144 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2024-209283

Published: 2024

Journal Articles

Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience

Gray Magee, Razan Mansour, Mark Chang, Shebli Atrash, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Al-Ola Abdallah, Barry Paul, Kimberly M Green, James A Davis, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 7034.

https://doi.org/10.1182/blood-2024-208085

Published: 2024

Journal Articles

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Barry Paul, Myra Robinson, James Symanowski, David M Foureau, Sarah Norek, Manisha Bhutani, Christopher Ferreri, Ami P Ndiaye, Jordan Robinson, Shebli Atrash, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, April Smith, Jessica Duda, Lance Cooper, Amani Kitali, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2024-208830

Published: 2024

Journal Articles

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7860.

https://doi.org/10.1182/blood-2024-210976

Published: 2024

Journal Articles

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Blood (2024) 144 (Supplement 1): 5170.5.

https://doi.org/10.1182/blood-2024-211053

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Darryl Chang, Myra Robinson, Rupali Bose, Hamid Ehsan, Arunkumar Krishnan, Shanice Borden, Peter M. Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Christopher Ferreri, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2024-209358

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, Darryl Chang, Barry Paul, Hira Shaikh, Christopher Strouse, Emily Struble, Andrew Vegel, James A Davis, Kimberly M Green, Hamza Hashmi, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Reed Friend

Blood (2024) 144 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2024-208799

Published: 2024

Journal Articles

Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis

Priyanka Venkatesh, Razan Mansour, Hamid Ehsan, Nausheen Ahmed, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shebli Atrash, Barry Paul

Blood (2024) 144 (Supplement 1): 3317.

https://doi.org/10.1182/blood-2024-207270

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Cindy Varga, Ferdous Ahmed, Marvin Knight, Manisha Bhutani, Barry Paul, Shebli Atrash, Peter M. Voorhees, Christopher Ferreri

Blood (2024) 144 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2024-204361

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Silver nanoparticles trigger proteotoxicity in multiple myeloma cells via a mechanism distinct from bortezomib and remain efective in BTZ-resistant myeloma

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers

Defining functional high-risk multiple myeloma in the era of modern induction therapy

Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only